Diamonds and Dogs
7/29/13
Dataram Corporation (DRAM)Dataram is getting rammed today, down 33.83% at $3.11. The large capacity memory company saw its shares get crushed after releasing full year and fourth quarter earnings. Revenue for the fourth quarter and full year were $6.2 million and $27.6 million respectively. That compares to $7.0 million and $36.1 million last year. The fourth quarter brought in a net loss of $1.6 million, which helped add to the full year net loss of $4.6 million. Dataram CEO, John Freeman said, "The primary factor impacting our financial results was a 33% industry wide decline in material cost per gigabyte." Dataram shares were able to stay in the middle of their 52-week range of $1.26-$6.19.
Synta Pharmaceuticals Corp. (SNTA)
Synta Pharmaceuticals is trading in the green today, up 41.30% at $7.15. The small molecule drug company saw its shares jump over $2.00 after a mid-stage study of its drug Ganetespib in breast cancer patients supported an expansion to a new phase of studies. The first study showed that four patients achieved and objective tumor response. Ganestespib is said to block a protein that assists other proteins in tumor development. Synta management said they want to move their trial size to 33 patients and continue to test the results of the drug. Synta shares are still off of their 52-week high of $11.88.
Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.